Elanco Animal Health Incorporated (NYSE:ELAN) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Elanco Animal Health Incorporated (NYSE:ELAN) have been assigned a consensus rating of “Moderate Buy” from the twelve analysts that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, two have given a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $27.6667.

A number of analysts recently weighed in on ELAN shares. Barclays started coverage on shares of Elanco Animal Health in a report on Tuesday, December 9th. They issued an “overweight” rating and a $30.00 price target for the company. JPMorgan Chase & Co. upped their price objective on Elanco Animal Health from $24.00 to $28.00 and gave the stock an “overweight” rating in a report on Thursday, February 19th. UBS Group reissued a “buy” rating on shares of Elanco Animal Health in a research note on Tuesday. Wall Street Zen upgraded Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a research report on Monday, January 19th. Finally, Morgan Stanley upped their price target on Elanco Animal Health from $22.00 to $24.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 25th.

Elanco Animal Health Stock Performance

Elanco Animal Health stock opened at $23.68 on Wednesday. The stock has a 50-day simple moving average of $24.50 and a 200 day simple moving average of $22.14. The stock has a market capitalization of $11.77 billion, a price-to-earnings ratio of -49.32, a P/E/G ratio of 3.04 and a beta of 1.83. The company has a quick ratio of 1.08, a current ratio of 2.17 and a debt-to-equity ratio of 0.60. Elanco Animal Health has a 12-month low of $8.02 and a 12-month high of $27.72.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings data on Tuesday, February 24th. The company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of $0.11 by $0.02. The firm had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.09 billion. Elanco Animal Health had a negative net margin of 4.92% and a positive return on equity of 7.16%. The company’s revenue was up 12.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.14 EPS. Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. On average, research analysts anticipate that Elanco Animal Health will post 0.91 earnings per share for the current fiscal year.

Insider Buying and Selling at Elanco Animal Health

In other Elanco Animal Health news, Director Lawrence Erik Kurzius bought 10,000 shares of Elanco Animal Health stock in a transaction dated Friday, December 12th. The shares were bought at an average price of $21.30 per share, with a total value of $213,000.00. Following the purchase, the director owned 131,773 shares of the company’s stock, valued at $2,806,764.90. This trade represents a 8.21% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Jeffrey N. Simmons purchased 22,000 shares of the stock in a transaction dated Thursday, December 11th. The shares were acquired at an average price of $21.75 per share, with a total value of $478,500.00. Following the transaction, the chief executive officer owned 167,000 shares in the company, valued at $3,632,250. This trade represents a 15.17% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last 90 days, insiders have purchased 43,450 shares of company stock valued at $937,883. 0.89% of the stock is currently owned by company insiders.

Institutional Trading of Elanco Animal Health

A number of institutional investors have recently bought and sold shares of the business. NewEdge Advisors LLC lifted its stake in shares of Elanco Animal Health by 133.7% in the 4th quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock valued at $25,000 after purchasing an additional 627 shares during the period. SJS Investment Consulting Inc. grew its stake in shares of Elanco Animal Health by 2,563.5% during the third quarter. SJS Investment Consulting Inc. now owns 1,385 shares of the company’s stock worth $28,000 after purchasing an additional 1,333 shares during the period. Huntington National Bank grew its stake in shares of Elanco Animal Health by 136.7% during the third quarter. Huntington National Bank now owns 1,882 shares of the company’s stock worth $38,000 after purchasing an additional 1,087 shares during the period. Root Financial Partners LLC increased its holdings in Elanco Animal Health by 50.7% in the fourth quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock valued at $40,000 after purchasing an additional 592 shares during the last quarter. Finally, Uniplan Investment Counsel Inc. acquired a new position in Elanco Animal Health in the fourth quarter valued at about $41,000. Institutional investors and hedge funds own 97.48% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.